Trials / Completed
CompletedNCT00193232
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
A Phase II Trial of Weekly Docetaxel and Bortezomib (Velcade; PS-341) in the Treatment of Patients With Advanced Hormone-Refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the effectiveness of weekly docetaxel/bortezomib as first-line chemotherapy for patients with advanced hormone-refractory prostate cancer.
Detailed description
Upon determination of eligibility, patients will be receive: * Docetaxel + Bortezomib Patients with objective responses or stable disease will continue treatment for eight courses or until disease progression is documented.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | |
| DRUG | Bortezomib |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2005-10-01
- Completion
- 2007-02-01
- First posted
- 2005-09-19
- Last updated
- 2010-07-28
Source: ClinicalTrials.gov record NCT00193232. Inclusion in this directory is not an endorsement.